Safety of CBD in Children and Young Adults with Treatment-Resistant Epilepsy
Cannabidiol (CBD) is the most abundant non-psychoactive cannabinoid in the cannabis plant. Animal studies demonstrate anticonvulsant efficacy in multiple species and models. Anecdotal reports suggest efficacy in children with treatment-resistant epilepsies (TRE), including Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS). We report current results in our expanded access treatment program.
SOURCE: American Epilepsy Society
AUTHORS: Orrin Devinsky, Elizabeth Thiele, Linda Laux, Daniel Friedman, Anup Patel, Judith Bluvstein, Michael Chez, Charuta Joshi, Roberta Cilio, Francis Filloux, Evan Fertig, Angus Wilfong, Paul D. Lyons, Yong Park, Robert Flamini, Matthew Wong, Ian Miller, Eric Marsh